Management of relapsed acute lymphoblastic leukemia in a patient with down syndrome: A case report
{{output}}
Children with Down syndrome (DS) have a 10-20-fold increased risk of acute lymphoblastic leukemia (ALL) and heightened chemotherapy toxicity. Blinatumomab, a bispecific CD19 × CD3 T-cell engager, offers targeted immunotherapy with reduced myelotoxicity. We de... ...
